Apex Healthcare Berhad Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Reports Property, Plant and Equipment Written Off for the Third Quarter Ended September 30, 2017
November 14, 2017 at 02:37 am EST
Share
Apex Healthcare Berhad announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported revenue MYR 157,730,000 against MYR 142,960,000 a year ago. Profit before tax was MYR 13,302,000 against MYR 11,536,000 a year ago. Net profit attributable to owners of the parent was MYR 11,270,000 against MYR 8,736,000 a year ago. Diluted earnings per share attributable to owners of the parent were 9.61 sen against 7.45 sen a year ago. In the third quarter of 2017, the group achieved revenue a growth of 10.3% when compared to the third quarter of 2016. This is helped by stronger contributions from the consumer products division as well as pharmaceutical sales to the public sector in Malaysia and Singapore. Expenses are in line with budget and in tandem with revenue growth. Share of profit from associate company Straits Apex Sdn Bhd is MYR 0.7 million, similar to that in the second quarter. Group profit before tax for the third quarter rose to MYR 13.3 million, 15.6% higher than the MYR 11.5 million achieved in the corresponding period in 2016.
For the nine months, the company reported revenue MYR 467,679,000 against MYR 437,123,000 a year ago. Profit before tax was MYR 39,667,000 against MYR 36,215,000 a year ago. Net profit attributable to owners of the parent was MYR 31,658,000 against MYR 28,198,000 a year ago. Diluted earnings per share attributable to owners of the parent were 27.00 sen against 24.06 sen a year ago. Net assets per share attributable to owners of the parent were MYR 2.82 as on September 30, 2017, compared with MYR 2.66 as on December 31, 2016. Net cash flows generated from operating activities was MYR 35,050,000 against MYR 28,288,000 a year ago. Purchase of property, plant and equipment & intangible assets was MYR 24,899,000 against MYR 7,351,000 a year ago. For the first nine months of 2017, the group achieved revenue a growth of 7% when compared to the same period in 2016. Steady revenue growth was achieved across all business units, with increased contributions from pharmaceutical sales to the Government sector and contract manufacturing services.
For the third quarter ended September 30, 2017, the company reported property, plant and equipment written off of MYR 1,000.
Apex Healthcare Berhad is a Malaysia-based healthcare company. The Company is focused on the development, manufacturing, wholesaling, marketing and distribution of pharmaceuticals, consumer healthcare products, and medical devices. It operates through three segments: Manufacturing, Distribution and Corporate. It is engaged in the manufacturing of pharmaceutical products. It is involved in the distribution of pharmaceutical and healthcare products. The Corporate segment comprises investments, properties and others. It is also engaged in the contract manufacturing of orthopedic devices. Its brands include XEPATM, AVO, AGNESIA, AEVA and HENNSON, and products bearing these brands are sold in approximately 16 territories worldwide. The Company's distribution channels reach hospitals, clinics, independent and chain pharmacies, supermarkets and health stores, enabling products to reach customers, namely doctors, pharmacists, nutritionists, retailers, and ultimately the patients or consumers.
Apex Healthcare Berhad Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Reports Property, Plant and Equipment Written Off for the Third Quarter Ended September 30, 2017
APEX HEALTHCARE 
